via OHSU
An innovative new technique that encourages cancer cells in the kidneys to self-destruct could revolutionise the treatment of the disease, a new study in the journal Pharmaceutics reports.
During this unique study, researchers from the University of Surrey and Sechenov First Moscow State Medical University in Russia investigated whether certain naturally occurring proteins within the body can be used to treat cancer.
Focusing on cathepsin S, a member of the lysosomal cathepsin proteins that are known to affect cancer progression, and p21 BAX, a protein that can stimulate cell destruction, researchers found that both can be deployed simultaneously to fight cancer cells in a two-pronged ‘attack.’ They act firstly by stopping the mechanism that makes certain treatments of the disease ineffective, and secondly by effectively encouraging cancerous cells to self-destruct.
This revolutionary approach targets two converging regulatory pathways that can sometimes be resistant to chemotherapy and has led to the development of a potential ground-breaking therapy using a novel peptide, CS-PEP1. Researchers found that this peptide inhibits both cathepsin S and its ability to break down the p21 BAX protein, resulting in the accumulation of p21 BAX, which encourages the death of cancer cells in the kidneys. The twin-track effect of this peptide can also override the molecular resistance often found during conventional chemotherapy treatment and offers a novel and effective approach in treating cancer.
An increased focus on therapeutic cancer treatments has signalled a move away from traditional methods such as chemotherapy and radiotherapy, as therapeutic treatments have been found to cause less harm to normal cells and fewer side effects for patients.
Professor Paul Townsend, Principal Investigator, Pro-Vice-Chancellor, and Executive Dean of the Faculty of Health and Medical Sciences at the University of Surrey, said: “Kidney cancer is a very difficult type of cancer to cure; there is an increased need to think innovatively to develop new techniques. We have now discovered that proteins already in the body can be manipulated to encourage cancerous cells to die. This is an extraordinary breakthrough and insight, and can be used to potentially inform the treatment of other types of aggressive cancers, such as cancers of the breast and prostate.”
Original Article: Innovative technique developed to destroy cancerous kidney cells
More from: University of Surrey | First Moscow State Medical University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Encouraging cancerous cells to self-destruct
- How ADAR1 mutation leads to self-destructive inflammation
They think that two different types of programmed cell self-destruction, as well as the production of inflammation signals, may all contribute. These could occur in varying degrees, depending on ...
- Treatment of stage 4 cancer based on the laws of physics
which is a method of high heat treatment that causes the destruction of malignant cells in the body. To begin with, a cancer cell has a structure that is damaged at a temperature between 41º-45º C.
- MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
“Non-melanoma skin cancers are the most common of all types of cancer and represent a ... was used for destruction of basal cell carcinoma, provides a preliminary clinical proof-of-concept ...
- MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced ...
- How the cell's waste management systems might be targeted to treat cancer
The faulty functioning of cellular waste management machinery can lead to cancer ... cell death during severe nutrient stress, where the cell triggers molecular mechanisms that lead to its ...
Go deeper with Google Headlines on:
Encouraging cancerous cells to self-destruct
Go deeper with Bing News on:
Kidney cancer
- Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) ...
- AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
Innate Pharma SA's (NASDAQ: IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ: AZN) did not meet a pre-defined threshold for efficacy. Based on this ...
- Lincoln Mom's Cancer Fight Focuses on Helping Others
ROB: A LINCOLN CANCER SURVIVOR HAS ENCOURAGING WORDS FOR THOSE STRUGGLING WITH A DIAGNOSIS. JULIE: SHE'S A MOTHER OF EIGHT AND A CHILD ADVOCATE WHO SAYS HER DIAGNOSIS MADE HER PASSION TO HELP OTHERS ...
- Setback: Bristol Myers drug combo fails to meet main goal in kidney cancer trial
Princeton: Bristol Myers Squibb has announced that Part A of the Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with ...
- Immunotherapy Duo Fails to Improve Disease-Free Survival in Patients With Kidney Cancer Following Surgery
Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study’s main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney ...